



We claim:

1. A compound of formula I





- 5 or pharmaceutically acceptable salts thereof wherein:

A is a structure i, ii, iii, or iv;



- 10 B is




- 15 W is $-N(H)C(X)-R_1$, Het, or $-Y-HET$, in which the Het or $-Y-HET$ is optionally substituted with $=S$ or $=O$, provided that when A is structure iv, W is not $-Y-HET$ or Het;

X is O or S;

Y is NH, O, or S;

Z is



R₁ is a) H,

b) NH₂,

c) NHC₁₋₄alkyl,

d) C₁₋₄ alkyl,

e) C₂₋₄ alkenyl,

f) O-C₁₋₄ alkyl,

i) S-C₁₋₄ alkyl, or

j) (CH₂)_s C₃₋₆ cycloalkyl, in which each occurrence of alkyl or


cycloalkyl in R₁ is optionally substituted by one, two or three halogens (F or Cl);

Each R₂ and R₃ is independently hydrogen, halogen (F or Cl), methyl or ethyl;

R₄ is H, CH₃ or F;

R₅ is H or C₁₋₄ alkyl;

R₆ is H, C₁₋₄ alkyl, or



or R₅ and R₆ together form an optionally substituted saturated heterocycle;

R₇ is H, or C₁₋₄ alkyl which can be optionally substituted by -OH, -NH₂, -NH-

C(=NH)-NH₂, -SH, -SCH₃, -COOH, -C(O)NH₂, phenyl which can be optionally substituted with -OH;


R₈ is H or CH₃;

R₉ is H, CH₃, -C(O)-CH(R₇)-NR₈R₈,




5

R₁₀ or R₁₁ is halo, C₁₋₄alkyl, CF₃, -CN, -NO₂, -OH, -O-C₁₋₄alkyl, -NH-S(O)_wC₁₋₄alkyl;




10

R₁₂ is H, C₁₋₄ alkyl, -S(O)₂-C₁₋₄alkyl,



or R₅ and R₁₂ together form a saturated heterocycle;



15

R₁₄ is -(CH₂)_tNHR₁₃, -OH, -OC₁₋₄alkyl;

m is 0, 1, 2, 3, 4;

n is 0, 1, 2, 3, 4 with the proviso that m plus n is 2, 3, 4, or 5;

p is 2, 3;

20

q is 1, 2;


r, s and t are independently 0, 1;

u and w are independently 0, 1, 2; and

provided that W is not Het or -Y-HET when Z is a, b, or d, and further provided that Z is not b when A is formula iii.


25

2. The compound of claim 1, wherein B is



3. The compound of claim 2, wherein p is 2.

5 4. The compound of claim 1, wherein B is



5. The compound of claim 4, wherein n and m are both 2.

10 6. The compound of claim 4, wherein n and m are both 1.

7. The compound of claim 4, wherein R₄ is -CH₃.

8. The compound of claim 2, wherein Z is (a).

15

9. The compound of claim 8, wherein R₅ and R₆ are C₁₋₄ alkyl.

10. The compound of claim 8, wherein R₅ and R₆ together form an optionally substituted saturated heterocycle.

20

11. The compound of claim 10, wherein R₅ and R₆ form an optionally substituted morpholinyl and piperazinyl.

12. The compound of claim 11, wherein R₅ and R₆ form a morpholinyl and piperazinyl each of which are substituted with C₁₋₄ alkyl.

25

13. The compound of claim 8, wherein u = 0.

14. The compound of claim 4, wherein Z is (a).

15. The compound of claim 14, wherein R₅ and R₆ are C₁₋₄ alkyl.
16. The compound of claim 14, wherein R₅ and R₆ together form an optionally substituted saturated heterocycle.
17. The compound of claim 16, wherein R₅ and R₆ form an optionally substituted morpholinyl and piperazinyl.
18. The compound of claim 17, wherein R₅ and R₆ form a morpholinyl and piperazinyl each of which are substituted with C₁₋₄ alkyl.
19. The compound of claim 14, wherein u = 0.
20. The compound of claim 2, wherein Z is (c).
21. The compound of claim 20, wherein R₁₀ is H.
22. The compound of claim 20, wherein R₁₁ is -C(O)-NH₂, -NHS(O)_uC₁₋₄alkyl, or -(CH₂)_t-NR₅R₁₂.
23. The compound of claim 22, wherein R₁₁ is -CH₂N(C₁₋₄alkyl)₂, -CH₂-saturated heterocycle, -CH₂-NH-C₁₋₄alkyl, -CH₂-N(C₁₋₄alkyl)-C(O)-CHR₇-NR₈R₉, -CH₂-NH-C(O)-C₁₋₄alkyl, -CH₂-NH-SO₂-(C₁₋₄alkyl), -CH₂-NH₂, or -NH-C(O)-CHR₇-NR₈R₉.
24. The compound of claim 20, wherein R₁₀ is ortho to R₁₁.
25. The compound of claim 20, wherein q is 1.
26. The compound of claim 4, wherein Z is (c).
27. The compound of claim 26, wherein R₁₀ is H.

28. The compound of claim 26, wherein R_{11} is $-C(O)-NH_2$, $-NHS(O)_u C_{1-4}alkyl$, or $-(CH_2)_t-NR_5R_{12}$.
- 5 29. The compound of claim 28, wherein R_{11} is $-CH_2N(C_{1-4}alkyl)_2$, $-CH_2$ -saturated heterocycle, $-CH_2-NH-C_{1-4}alkyl$, $-CH_2-N(C_{1-4}alkyl)-C(O)-CHR_7-NR_8R_9$, $-CH_2-NH-C(O)-C_{1-4}alkyl$, $-CH_2-NH-SO_2-(C_{1-4}alkyl)$, $-CH_2-NH_2$, or $-NH-C(O)-CHR_7-NR_8R_9$.
- 10 30. The compound of claim 26, wherein q is 1.
31. The compound of claim 2, wherein Z is (b).
32. The compound of claim 31, wherein R_{14} is $-OC_{1-4}alkyl$, $-OH$, or $-NH-C(O)-$
15 $CH(R_7)-NR_8R_9$.
33. The compound of claim 4, wherein Z is (b).
34. The compound of claim 33, wherein R_{14} is $-OC_{1-4}alkyl$, $-OH$, or $-NH-C(O)-$
20 $CH(R_7)-NR_8R_9$.
35. The compound
- $N-[(5S)-3-\{4-[4-((4-[(Diethylamino)methyl]phenoxy)acetyl) piperazin-1-yl]-3-fluorophenyl\}-2-oxo-1,3-oxazolidin-5-yl)methyl] propanethioamide;$
- 25 $N-[(5S)-3-\{4-[4-((4-[(Diethylamino)methyl]phenoxy)acetyl) piperazin-1-yl]-3-fluorophenyl\}-2-oxo-1,3-oxazolidin-5-yl)methyl] cyclopropanecarbothioamide;$
- $N-[(5S)-3-\{4-[4-((4-[(Diethylamino)methyl]phenoxy)acetyl) piperazin-1-yl]-3-fluorophenyl\}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide;$
- $N-[(5S)-3-\{4-[4-((4-[(Dimethylamino)methyl]phenoxy)acetyl) piperazin-1-yl]-3-$
30 $fluorophenyl\}-2-oxo-1,3-oxazolidin-5-yl)methyl] propanethioamide;$
- $N-[(5S)-3-\{4-[4-((4-[(Dimethylamino)methyl]phenoxy)acetyl) piperazin-1-yl]-3-fluorophenyl\}-2-oxo-1,3-oxazolidin-5-yl)methyl] cyclopropanecarbothioamide;$

- N-(((5*S*)-3-{4-[4-({4-[(Dimethylamino)methyl]phenoxy} acetyl) piperazin-1-yl]-3-fluorophenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide;
- N-({(5*S*)-3-[3-Fluoro-4-(4-{[4-(morpholin-4-ylmethyl)phenoxy] acetyl} piperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl) propanethioamide;
- 5 N-({(5*S*)-3-[3-Fluoro-4-(4-{[4-(morpholin-4-ylmethyl)phenoxy] acetyl} piperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl) cyclopropanecarbothioamide;
- N-({(5*S*)-3-[3-Fluoro-4-(4-{[4-(morpholin-4-ylmethyl)phenoxy] acetyl} piperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)acetamide;
- 10 N-(((5*S*)-3-{3-Fluoro-4-[4-({4-[(4-methylpiperazin-1-yl)methyl]phenoxy} acetyl)piperazin-1-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl) propanethioamide;
- N-(((5*S*)-3-{3-Fluoro-4-[4-({4-[(4-methylpiperazin-1-yl)methyl]phenoxy} acetyl)piperazin-1-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)cyclopropanecarbothioamide;
- 15 N-(((5*S*)-3-{3-Fluoro-4-[4-({4-[(4-methylpiperazin-1-yl)methyl]phenoxy} acetyl)piperazin-1-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl) acetamide;
- N-(((5*S*)-3-{4-[4-(4-{4-[(Dimethylamino)methyl]phenyl}-4-oxobutanoyl)-1-piperazinyl]-3-fluorophenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide;
- N-(((5*S*)-3-{4-[4-(4-{4-[(Dimethylamino)methyl]phenyl}-4-oxobutanoyl)-1-piperazinyl]-3-fluorophenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)cyclopropanecarbothioamide;
- 20 N-(((5*S*)-3-{4-[4-(4-{4-[(Dimethylamino)methyl]phenyl}-4-oxobutanoyl)-1-piperazinyl]-3-fluorophenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;
- N-({(5*S*)-3-[3-Fluoro-4-(4-{4-[4-(4-morpholinylmethyl)phenyl]-4-oxobutanoyl}-1-piperazinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)propanethioamide;
- 25 N-({(5*S*)-3-[3-Fluoro-4-(4-{4-[4-(4-morpholinylmethyl)phenyl]-4-oxobutanoyl}-1-piperazinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)acetamide;
- N-({(5*S*)-3-[3-Fluoro-4-(4-{4-[4-(4-morpholinylmethyl)phenyl]-4-oxobutanoyl}-1-piperazinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)cyclopropanecarbothioamide;

N-(((5S)-3-{3-Fluoro-4-[4-(4-{4-[(methylamino)methyl]phenyl}-4-oxobutanoyl)piperazin-1-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;
 N¹-(4-{4-[4-(4-{(5S)-5-[(Acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)-piperazin-1-yl]-4-oxobutanoyl}benzyl)-N¹-methylglycinamide;
 5 N¹-(4-{4-[4-(4-{(5S)-5-[(Acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)piperazin-1-yl]-4-oxobutanoyl}benzyl)-N¹,N²,N²-trimethylglycinamide;
 N¹-(4-{4-[4-(4-{(5S)-5-[(Acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)piperazin-1-yl]-4-oxobutanoyl}benzyl)-N²,N²-dimethylglycinamide;
 N¹-(4-{4-[4-[2-Fluoro-4-{(5S)-2-oxo-5-[(propanethiolylamino)methyl]-1,3-oxazolidin-3-yl}phenyl)piperazin-1-yl]-4-oxobutanoyl}benzyl)-N²,N²-
 10 dimethylglycinamide;
 (S)-N¹-(4-{4-[4-(2-Fluoro-4-{(5S)-2-oxo-5-[(propanethiolylamino)methyl]-1,3-oxazolidin-3-yl}phenyl)piperazin-1-yl]-4-oxobutanoyl}benzyl)alaninamide;
 (S)-N¹-(4-{4-[4-(4-{(5S)-5-[(Acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)piperazin-1-yl]-2-oxobutanoyl}benzyl)alaninamide;
 15 (S)-N¹-(4-{4-[4-(2-Fluoro-4-{(5S)-2-oxo-5-[(propanethiolylamino)methyl]-1,3-oxazolidin-3-yl}phenyl)piperazin-1-yl]-4-oxobutanoyl}benzyl)glycinamide;
 (S)-Alanyl-(S)-N¹-(4-{4-[4-(2-fluoro-4-{(5S)-2-oxo-5-[(propanethiolylamino)methyl]-1,3-oxazolidin-3-yl}phenyl)piperazin-1-yl]-4-oxobutanoyl}benzyl)alaninamide;
 20 (S)-Alanyl-(S)-N¹-(4-{4-[4-(4-{(5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)piperazin-1-yl]-4-oxobutanoyl}benzyl)alaninamide;
 N-(4-{4-[4-(4-{(5S)-5-[(Acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)-1-piperazinyl]-4-oxobutanoyl}benzyl)acetamide;
 N-(4-{4-[4-(2-Fluoro-4-{(5S)-2-oxo-5-[(propanethiolylamino)methyl]-1,3-oxazolidin-3-yl}phenyl)-1-piperazinyl]-4-oxobutanoyl}benzyl)acetamide;
 25 3-yl}phenyl)-1-piperazinyl]-4-oxobutanoyl}benzyl)acetamide;
 N-{[(5S)-3-(3-Fluoro-4-{4-[4-(4-{[(methylsulfonyl)amino]methyl}phenyl)-4-oxobutanoyl]-1-piperazinyl}phenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl}acetamide;
 N-{[(5S)-3-(3-Fluoro-4-{4-[4-(4-{[(methylsulfonyl)amino]methyl}phenyl)-4-oxobutanoyl]-1-piperazinyl}phenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl}propanethioamide;
 30

N-((5*S*)-3-[4-(4-{4-[4-(Aminomethyl)phenyl]-4-oxobutanoyl}-1-piperazinyl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide;

N-((5*S*)-3-[4-(4-{4-[4-(Aminomethyl)phenyl]-4-oxobutanoyl}-1-piperazinyl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;

5 N¹-(4-{4-[4-(4-{(5*S*)-5-[(Acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl]-2-fluorophenyl)piperazin-1-yl]-4-oxobutanoyl}benzyl)glycinamide;

2-[3-methyl-3-(4-{(5*S*)-2-oxo-5-[(propionylamino)methyl]-1,3-oxazolidin-3-yl}phenyl)azetidin-1-yl]-2-oxoethyl 4-(aminomethyl)benzamide;

10 N-([(5*S*)-3-(4-{1-[4-(4-aminophenyl)-4-oxobutanoyl]-3-methylazetidin-3-yl}phenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide;

N-((5*S*)-3-[4-(1-{4-[4-(glycylamino)phenyl]-4-oxobutanoyl}-3-methylazetidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide;

N-([(5*S*)-3-(4-{1-[4-(4-aminophenyl)-4-oxobutanoyl]-3-methylazetidin-3-yl}-3-fluorophenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide;

15 N~1~-(4-{4-[3-(4-{(5*S*)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl]-2-fluorophenyl)-3-methylazetidin-1-yl]-4-oxobutanoyl}phenyl)glycinamide;

2-[3-(4-{(5*S*)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)-3-methylazetidin-1-yl]-2-oxoethyl-4-(aminomethyl)benzamide;

20 N-([(5*S*)-3-(3-Fluoro-4-{4-[4-(4-methoxyphenyl)butanoyl]piperazine-1-yl}phenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide;

N-([(5*S*)-3-(3-Fluoro-4-{4-[4-(4-hydroxyphenyl)butanoyl]piperazin-1-yl}phenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide;

2,2-Difluoro-N-([(5*S*)-3-(3-fluoro-4-{4-[4-(4-methoxyphenyl)butanoyl]piperazin-1-yl}phenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl]ethanethioamide;

25 N-([(5*S*)-3-(4-{4-[4-(4-Bromophenyl)-4-oxobutanoyl]-1-piperazinyl}-3-fluorophenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide;

N-([(5*S*)-3-(4-{4-[4-(4-Bromophenyl)-4-oxobutanoyl]-1-piperazinyl}-3-fluorophenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl]ethanethioamide;

- N-{[(5*S*)-3-(4-{4-[4-(4-Cyanophenyl)-4-oxobutanoyl]-1-piperazinyl}-3-fluorophenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl}acetamide;
- 4-{4-[4-(4-{(5*S*)-5-[(Acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)-1-piperazinyl]-4-oxobutanoyl}benzamide;
- 5 4-{4-[4-(4-{(5*S*)-5-[(Ethanethiolylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)-1-piperazinyl]-4-oxobutanoyl}benzamide;
- N-{[(5*S*)-3-(4-{4-[4-(4-Chlorophenyl)-4-oxobutanoyl]-1-piperazinyl}-3-fluorophenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl}acetamide;
- 10 N-{[(5*S*)-3-(4-{4-[4-(4-chlorophenyl)-4-oxobutanoyl]-1-piperazinyl}-3-fluorophenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl}ethanethioamide;
- N-[(5*S*)-3-{3-Fluoro-4-[4-(4-{4-[(methylsulfonyl)amino]phenyl}-4-oxobutanoyl)-1-piperazinyl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanethioamide;
- N-[(5*S*)-3-{3-Fluoro-4-[4-(4-{4-[(methylsulfonyl)amino]phenyl}-4-oxobutanoyl)-1-piperazinyl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide. N-(4-{4-[4-(2-
- 15 Fluoro-4-{(5*S*)-2-oxo-5-[(propanethiolylamino)methyl]-1,3-oxazolidin-3-yl}phenyl)-1-piperazinyl]-4-oxobutanoyl}phenyl)acetamide;
- 2-Amino-N-(4-{4-[4-(2-fluoro-4-{(5*S*)-2-oxo-5-[(propanethiolylamino)methyl]1,3-oxazolidin-3-yl}phenyl)-1-piperazinyl]-4-oxobutanoyl}phenyl)acetamide;
- N-(4-{4-[4-(4-{(5*S*)-5-[(Acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)-1-piperazinyl]-4-oxobutanoyl}phenyl)-2-aminoacetamide;
- 20 N-(4-{4-[4-(4-{(5*S*)-5-[(Acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)-1-piperazinyl]-4-oxobutanoyl}phenyl)-(2*S*)-2-aminopropanamide;
- N-1-(4-{4-[4-(4-{(5*S*)-5-[(Ethanethiolylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)piperazin-1-yl]-4-oxobutanoyl}phenyl)-(S)-alaninamide;
- 25 N¹-[4-(5-{4-[4-((5*S*)-5-[(2,2-Difluoroethanethioyl)amino]methyl)-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]piperazin-1-yl]-5-oxopentanoyl}phenyl]glycinamide;

- N^1 -(4-{5-[4-(4-{(5*S*)-5-[(Acetyl amino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)piperazin-1-yl]-5-oxopentanoyl}phenyl)glycinamide;
- N -(4-{4-[4-(4-{(5*S*)-5-[(Acetyl amino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)-1-piperazinyl]-4-oxobutyl}phenyl)-2-aminoacetamide;
- 5 2-Amino- N -(4-{4-[4-(2-fluoro-4-{(5*S*)-2-oxo-5-[(propanethiolyl amino)methyl]-1,3-oxazolidin-3-yl}phenyl)-1-piperazinyl]-4-oxobutyl}phenyl)acetamide;
- (*S*)-2-Amino- N -(4-{4-[4-(2-fluoro-4-{(5*S*)-2-oxo-5-[(propanethiolyl amino)methyl]-1,3-oxazolidin-3-yl}phenyl)-1-piperazinyl]-4-oxobutyl}phenyl)propanamide;
- N -(4-{4-[4-(4-{(5*S*)-5-[(Acetyl amino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)piperazin-1-yl]-4-oxobutyl}phenyl)-2-(dimethyl amino)acetamide;
- 10 N -(4-{4-[4-(4-{(5*S*)-5-[(Ethanethiolyl amino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)piperazin-1-yl]-4-oxobutyl}phenyl)-2-(dimethyl amino)acetamide;
- N^1 -(3-{4-[4-(4-{(5*S*)-5-[(Acetyl amino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)piperazin-1-yl]-1-hydroxy-4-oxobutyl}phenyl)glycinamide;
- 15 N^1 -[3-(4-{4-[4-((5*S*)-5-[(2,2-Difluoroethanethiolyl)amino]methyl)-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]piperazin-1-yl)-4-oxobutanoyl]phenyl]glycinamide;
- N -{[(5*S*)-3-(3-Fluoro-4-{4-[4-(3-nitrophenyl)-4-oxobutanoyl]piperazin-1-yl}phenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}actamide;
- N^1 -(3-{4-[4-(4-{(5*S*)-5-[(Acetyl amino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)piperazin-1-yl]-4-oxobutanoyl}phenyl)glycinamide;
- 20 N -{[(5*S*)-3-(4-{4-[4-(2-Aminophenyl)-4-oxobutanoyl]piperazin-1-yl}-3-fluorophenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide;
- N -{[(5*S*)-3-(4-{4-[(5-Amino-1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)acetyl]piperazin-1-yl}-3-fluorophenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide;
- 25

N¹-(2-{2-[4-(4-{(5*S*)-5-[(Acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]piperazin-1-yl}-2-oxoethyl)-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl)glycinamide; or

5 N¹-[2-(3-{4-[4-((5*S*)-5-[(2,2-Difluoroethanethiolyl)amino]methyl)-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]piperazin-1-yl}-3-oxopropyl)-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl) glycinamide.

36. A method for the treatment of microbial infections in mammals comprising administration of an effective amount of compound of claim 1 to said mammal.

10

37. The method of claim 36 wherein said compound of claim 1 is administered to the mammal orally, parenterally, transdermally, or topically in a pharmaceutical composition.

15 38. The method of claim 37 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

39. The method of claim 37 wherein said compound is administered in an amount of from about 1 to about 50 mg/kg of body weight/day.

20

40. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.